nl-atn1-002
Nucleic acidexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 21, 2024 (NCT06706388)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Atrophin-1ANTISENSE INHIBITOR
ATN1 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07084311 | Phase 1/Phase 2 (Phase 2) | Oct 24, 2024 | Hawaii Pacific Health, n-Lorem Foundation |
| NCT06706388 | Phase 1/Phase 2 (Phase 2) | Feb 21, 2024 | Columbia University, n-Lorem Foundation |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| n-Lorem Foundation | Academic/Hospital | 2 | 2 | 1 | 2024 |
| Columbia University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Hawaii Pacific Health | Academic/Hospital | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1